Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Rijksmuseum raised its target price for Microsoft (MSFT.O) from $540 to $630.
2026-10-27
Rijksmuseum raised its target price for Microsoft (MSFT.O) from $540 to $630.
Back
Other News
2026-10-27
A Reuters poll predicts that the average gold price will be $4,495 per ounce in 2026 and $4,650 in 2027. The average silver price is projected to be $70.30 per ounce in 2026 and $66.75 in 2027.
A Reuters poll predicts that the average gold price will be $4,495 per ounce in 2026 and $4,650 in 2027. The average silver price is projected to be $70.30 per ounce in 2026 and $66.75 in 2027.
2026-10-27
China's National Joint Drug Procurement Office on Oct. 26 revoked the national procurement winning status for letrozole tablets produced by Eugia Pharma Specialities Limited and gadoterate meglumine injection produced by JSC Farmak. The office said b
China's National Joint Drug Procurement Office on Oct. 26 revoked the national procurement winning status for letrozole tablets produced by Eugia Pharma Specialities Limited and gadoterate meglumine injection produced by JSC Farmak. The office said both applicants recently reported they could not continue to supply the products and, after supervisory interviews, still failed to meet medical institutions' demand. Eugia and its applicant Hangzhou Ketu Supply Chain Co. were placed on the violations list and barred from participating in national drug procurement for four years; JSC Farmak and its applicant Shanghai Liyi Pharmaceutical Technology Co. were likewise listed and barred for two years.
Chat with us
, powered by
LiveChat